NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, P.A. announces that it is investigating potential securities fraud claims against The Medicines Company (Nasdaq:MDCO) resulting from allegations that the Company may have issued materially misleading business information to the investing public.
On February 10, 2014, the U.S. Food and Drug Administration (“FDA”) issued a report concerning Medicines Co. drug candidate Cangrelor, designed to prevent blood clots. The report indicated that Cangrelor was not shown to be as good or superior to a rival drug and a new trial should be conducted before the drug is considered for approval. The report also states that the CHAMPION trials “were conducted unethically” and Cangrelor should not be approved “on that fact alone.” On this news, shares of The Medicines Company fell $1.80 per share, or by approximately 5%, to close at $32.42 on February 10, 2014.
The Rosen Law Firm is preparing a class action lawsuit as a result of this adverse information. If you purchased Medicines Co. securities, you may visit the website at http://rosenlegal.com to join the action. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail at firstname.lastname@example.org or email@example.com.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.